141 related articles for article (PubMed ID: 36815510)
41. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
42. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
Chen L; Yang QC; Li YC; Yang LL; Liu JF; Li H; Xiao Y; Bu LL; Zhang WF; Sun ZJ
Cancer Immunol Res; 2020 Feb; 8(2):179-191. PubMed ID: 31771985
[TBL] [Abstract][Full Text] [Related]
43. Expression of B7-H3 and TIM-3 in gastric-type endocervical adenocarcinoma: prevalence, association with PD-L1 expression, and prognostic significance.
Sun Y; Zhou X; Lucas E; Chen L; Zhang H; Chen H; Zhou F
J Pathol Clin Res; 2024 Jan; 10(1):e345. PubMed ID: 37798754
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
45. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
[No Abstract] [Full Text] [Related]
46. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
47. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
48. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
51. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
[TBL] [Abstract][Full Text] [Related]
52. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
[TBL] [Abstract][Full Text] [Related]
53. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
55. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
56. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Sato F; Ono T; Kawahara A; Kawaguchi T; Tanaka H; Shimamatsu K; Kakuma T; Akiba J; Umeno H; Yano H
J Clin Pathol; 2019 Aug; 72(8):542-549. PubMed ID: 31113825
[TBL] [Abstract][Full Text] [Related]
57. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Enwere EK; Kornaga EN; Dean M; Koulis TA; Phan T; Kalantarian M; Köbel M; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Mod Pathol; 2017 Apr; 30(4):577-586. PubMed ID: 28059093
[TBL] [Abstract][Full Text] [Related]
58. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
59. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
Qian S; Xu J; Zhao S; Yang P; Yang C
Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
[TBL] [Abstract][Full Text] [Related]
60. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
